Ozmosi | OCU-410 Drug Profile
Drug Profile
Using advanced filters...

OCU-410

Alternative Names: OCU-410, OCU410, OCU 410, AAV-RORA, OCU410ST
Clinical Status: Active
Latest Update: 2026-08-19
Latest Update Note: Clinical Trial Update

Product Description

OCU410 is the second drug candidate from Ocugen's Modifier Gene Therapy Platform, which is expected to enter clinical trials in 2022. Ocugen recently announced a collaboration with CanSinoBIO for the chemistry, manufacturing, and controls ("CMC") development and manufacture of clinical supplies of OCU410 to advance the program. Modifier Gene Therapy is different from traditional gene augmentation. (Sourced from: https://ir.ocugen.com/news-releases/news-release-details/ocugen-inc-present-pre-clinical-data-ocu410-2nd-annual-dry-amd)

Mechanisms of Action: Gene Therapy, RORA

Novel Mechanism: Yes

Modality: Gene Therapy

Route of Administration: Injection

FDA Designation: Orphan Drug - Stargardt Disease
Regenerative Medicine Advanced Therapy - Geographic Atrophy|Macular Degeneration *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Company: Ocugen
Company Location: Eastern America
Company Founding Year: 2013
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for OCU-410

Countries in Clinic: United States

Active Clinical Trial Count: 3

Recent & Upcoming Milestones

  • Clinical Outcomes Expected - Ocugen announced they will present P2 Stargardt Disease results in 2Q27 for OCU-410
  • Clinical Outcomes Expected - Ocugen announced they will present P3 Neovascular age-related macular degeneration|Stargardt Disease results in YE27 for OCU-410
  • Clinical Outcomes Reported - Ocugen presented P1 Geographic Atrophy|Stargardt Disease results on 2026-10-01 for OCU-410

Highest Development Phases

Phase 3: Macular Degeneration|Stargardt Disease

Phase 2: Geographic Atrophy

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

NCT06018558

ArMaDa

P2

Active, not recruiting

Geographic Atrophy

2026-02-03

39%

2026-08-01

Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments

NCT07770828

OCU410-301

P3

Recruiting

Macular Degeneration

2028-07-30

2%

2026-08-20

Primary Endpoints|Treatments

NCT05956626

GARDian3

P3

Active, not recruiting

Stargardt Disease

2026-09-28

2%

2026-04-07

Primary Endpoints|Treatments|Trial Status